

# Safe and effective treatments are needed for cryptosporidiosis, a truly neglected tropical disease

Ian H Gilbert,<sup>1</sup> Sumiti Vinayak,<sup>2</sup> Boris Striepen ,<sup>3</sup> Ujjini H Manjunatha,<sup>4</sup> Ibrahim A Khalil,<sup>5</sup> Wesley C Van Voorhis ,<sup>6</sup> Cryptosporidiosis Therapeutics Advocacy Group CTAG<sup>7</sup>

**To cite:** Gilbert IH, Vinayak S, Striepen B, *et al*. Safe and effective treatments are needed for cryptosporidiosis, a truly neglected tropical disease. *BMJ Glob Health* 2023;**8**:e012540. doi:10.1136/bmjgh-2023-012540

**Handling editor** Seye Abimbola

Received 19 May 2023

Accepted 25 June 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>DDU, University of Dundee, Dundee, UK

<sup>2</sup>Department of Pathobiology, College of Veterinary Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois, USA

<sup>3</sup>Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA

<sup>4</sup>Global Health, Novartis Institutes for BioMedical Research, Inc, Emeryville, California, USA

<sup>5</sup>Department of Health, State of Washington, Seattle, Washington, USA

<sup>6</sup>Medicine, Div AID, University of Washington, Seattle, Washington, USA

<sup>7</sup>Various Institutions, Various Cities, Various Countries

## Correspondence to

Wesley C Van Voorhis; wesley@uw.edu


Early childhood cryptosporidiosis causes acute disease and mortality, as well as lasting malnutrition and developmental delay. However, there are no safe and effective therapeutics for cryptosporidiosis. Developing such therapeutics will save hundreds and thousands of lives in young children and spare millions of disability-adjusted life years lost (DALYs). This white paper discusses the global public health impact of *Cryptosporidium* infections, the immediate need for more effective treatment of cryptosporidiosis, and recent advances that are yielding multiple promising leads for therapeutic development. We will discuss the remaining challenges, which is to complete the preclinical and clinical steps to bring these novel therapeutics to children in urgent need of treatment.

Diarrhoeal diseases cause unacceptable loss of life, mainly among infants and children in low-income and middle-income countries (LMICs). The Global Enteric Multicentre Study (GEMS) revealed the pathogens associated with diarrhoea in children in LMICs.<sup>1</sup> Of particular prevalence, as cause of severe disease, were rotavirus, *Cryptosporidium spp*, enterotoxigenic *Escherichia coli* and *Shigella*. The parasite *Cryptosporidium* (*C. hominis* and *C. parvum*) remains one of the most lethal pathogens for malnourished infants and children, with a devastating health impact on those under 2 years of age. The GEMS study estimated about 7.5 million cases of *Cryptosporidium* infection occur every year within this population in Africa and Asia resulting in over 200 000 *Cryptosporidium*-attributable deaths due to moderate-to-severe diarrhoea, with an excess of 59 000 deaths compared with children with similar symptoms that were *Cryptosporidium* negative.<sup>2</sup>

*Cryptosporidium* infection in these malnourished children is also significantly associated

with debilitating stunted growth contributing to excess mortality.<sup>3-6</sup> This *Cryptosporidium*-associated stunting and wasting leads to poor physical and neurological health with poor childhood development, resulting in a lasting effect on population health in LMICs.<sup>5</sup> This burden falls disproportionately on children in sub-Saharan Africa, but also in South America and Asia (figure 1). In 2018, Dr Khalil and coworkers at the Institute for Health Metrics and Evaluation reported that acute *Cryptosporidium* infection was associated with an annual loss of greater than 4.2 million DALYs.<sup>3</sup> Each DALY represents the loss of a full year of healthy life. In 2019, the Global Burden of Disease study revised the number of deaths and DALYs attributable to *Cryptosporidium* to 133 422 deaths and 8.2 million DALYs per year, taking into account both the acute and long-term effects of *Cryptosporidium* infection.<sup>7</sup> To put this in perspective with other diarrhoeal diseases within the same 2019 study, cholera is attributable to less deaths (117 000) and DALYs (7.1 million), and both *Shigella* and Rotavirus were responsible for only slightly more deaths (148 000 and 235 000, respectively) and DALYs (10 million and 17 million).<sup>7</sup> In contrast to cryptosporidiosis, vaccines or treatments are available or in advanced development for these infections. Notably, when comparing *Cryptosporidium* with WHO recognised neglected tropical diseases (NTDs), it greatly exceeds both the deaths and DALYs associated with essentially all of these diseases (figure 2).<sup>8</sup>

Effective treatment to mitigate the impact of cryptosporidiosis on child health and survival is woefully lacking. Nitazoxanide is the only US Food and Drug Administration (FDA) approved therapeutic for treating *Cryptosporidium* infection. It has been shown to be ineffective in immunocompromised individuals




**Figure 1** Total (acute and long-term) *Cryptosporidium* DALYs per 1000 child-years among children under 5 (GBD estimates and geographic distribution, Ibrahim Khalil). DALYs after accounting for undernutrition-associated DALYs due to cryptosporidiosis.<sup>7</sup> DALYs, disability-adjusted life years lost; GBD, Global Burden of Disease.

and less than 50% effective in malnourished children less than 5 years old.<sup>9</sup> Nitazoxanide in vitro does have direct activity against *Cryptosporidium*, but only at concentrations much higher than those achieved during therapy. Animal models suggest nitazoxanide likely relies on stimulation of the immune system to expel *Cryptosporidium*. Those most threatened by infection, malnourished children and the immunocompromised cannot mount the immune response required for effective therapy with nitazoxanide.<sup>10 11</sup>

This unmet medical need inspired a recent surge in *Cryptosporidium* research that has yielded the modern experimental tools and facile animal models needed to discover antiparasitic compounds and validate their targets.<sup>12–23</sup>

Most importantly, safe and effective compounds in preclinical models with direct action against *Cryptosporidium* have emerged.<sup>13 15 16 18 24–31</sup> This represents a major advance, significantly expanding the quality and quantity of the portfolio. Multiple drug candidates are now progressing towards preclinical development and clinical trials at an uneven pace (table 1). The initial high-risk research that led to these compounds was conducted by multiple academic and industry groups, often with extensive academic and industry collaboration and with governmental and philanthropic support. Now further investments are needed to capitalise on this rich portfolio and accelerate the development and registration of transformative therapies for this largely unmet medical need.



**Figure 2** Infectious disease deaths and DALYs by WHO region.<sup>8</sup> There are estimated to be 133 000 deaths per year and 820 000 DALYs due to cryptosporidiosis (pink), which greatly exceed the WHO NTDs, note differences in scales. DALYs, disability-adjusted life years lost; NTDs, neglected tropical diseases.

**Table 1** Examples of compounds in preclinical development

Inhibitor/compound series	Lead laboratory	Effective in animal models	Stage	References
Phosphatidylinositol 4-kinase	Novartis	Yes	Phase 1 human trials	15
Bumped kinase inhibitors	University of Washington	Yes	Preclinical candidate	26
Lysyl tRNA synthetase	DDU, University of Dundee	Yes	Late lead profiling	13
Benzoxaborole	Anacor, University of Vermont	Yes	Late lead profiling	29
SLU-2633/MMV665917	St. Louis University, University of Vermont	Yes	Late lead profiling	31
Phenylalanine tRNA synthetase	BROAD Institute, University of Vermont	Yes	Early lead profiling	16

A vaccine that prevents *Cryptosporidium* morbidity and mortality would be of great benefit to childhood health in LMICs, and research towards vaccination should be supported. However, natural immunity to *Cryptosporidium* is non-sterile and requires multiple infections, highlighting the parasite's potential to evade immunity. Developing vaccines to address parasitic infections, like *Cryptosporidium*, has been difficult and we are probably at least a decade from having a safe and effective vaccine. Developing a therapeutic will allow us to address child health in LMICs in a much faster time frame. Even after vaccines arrive, there will be a need for drugs because of insufficient protection, lack of coverage and challenges of roll-out and delivery.

Multiple recent efforts centred in academia, industry and in joint venture have produced highly promising late preclinical therapeutic leads that are markedly superior to nitazoxanide in preclinical models (table 1). This is a truly transformative advance in both quality and quantity offering a viable path towards treatment. These compounds now require varying degrees of advanced preclinical testing, and clinical trials performed before they can be deployed. The target population is infants, however, for a proof of concept (phase 2a) study, testing in infants is inadvisable due to safety, pharmacokinetic and ethical challenges. Cryptosporidiosis is typically rare in adults living in high transmission areas due to acquired immunity, except in HIV/AIDS patients. Recent advances in the clinical evaluation of novel antimalarials provide critical guidance forward. Human challenge models using healthy volunteers have proven an invaluable tool<sup>32 33</sup> providing an insight into efficacy without the risks associated with highly vulnerable populations. Multiple such studies have been conducted with *Cryptosporidium* in the past and were found to be safe<sup>34–36</sup> and the model has recently be updated.<sup>37</sup> We support a clinical trial plan proposed in which the proof of concept (phase 2a study) is conducted with volunteers intentionally infected with *C. parvum*, followed by phase 2b and 3 studies in children in endemic areas.<sup>37</sup>

Since malaria and *Cryptosporidium* belong to the same phylum Apicomplexa, they share some conserved drug targets, and thus there is a synergy possibility in research

and development of malaria and *Cryptosporidium* therapeutics. But like malaria, *Cryptosporidium* may develop resistance to monotherapy, given the high numbers of parasites during infection. Indeed, emergence of resistance has been documented in the newborn calf model of infection for one compound that targets methionyl-tRNA-synthetase.<sup>38</sup> Therefore, it is probably necessary to take several compounds through clinical development to provide the possibility of combination treatment (table 1). There are also possibilities for synergy with the animal health market, particularly for dairy cattle, where in some areas nearly 100% of newborn calves acquire *C. parvum* infection, and *Cryptosporidium* infection has been shown to lead to lasting weight loss and reduced milk production.<sup>39–41</sup>

A challenge to be addressed is the clinical usage of an anti-*Cryptosporidium* drug. Studies indicate that there are multiple causes of diarrhoea; as indicated above, causative organisms include *Shigella spp*, enterotoxigenic *E. coli*, *Campylobacter jejuni* and rotavirus. There is current compelling evidence of unmet therapeutic need for enteric cryptosporidiosis found in three patient groups: (1) young children aged 0–24 months in LMICs; (2) malnourished children under age 5 and (3) immunosuppressed individuals of any age.<sup>42 43</sup> A recent publication outlines an effective therapeutic could be used to reduce the large burden of *Cryptosporidium* in LMICs (table 2).<sup>42</sup> *Cryptosporidium* therapy could be used syndromically, for instance in children less than 2 years old with moderate-to-severe diarrhoea, probably combined with an antibacterial to cover the major treatable causes, *E. coli*, *Shigella spp* and *C. jejuni*. Treatment could be carried out with a diagnostic, such as a point-of care rapid antigen detection test, or a PCR, similar to that used in SARS-CoV-2 detection. This diagnostic-directed therapy might be especially helpful in malnourished children less than 5 years old, where asymptomatic and mildly symptomatic *Cryptosporidium* has been shown to be highly associated with poor outcomes, such as stunting, poor physical and mental development and excess deaths from other causes. These diagnostic tools are available now, and the rapid antigen detection test can be done at small village clinics where sick and malnourished children are first

**Table 2** Use case scenarios for an anti-*Cryptosporidium* therapeutic for LMICs <sup>adapted from 42</sup>

Target population	Disease burden	Potential treatment sites	Potential treatment strategies	Current applicability: nitazoxanide
Young children aged 0–24 months	7.5 million cases with moderate-to-severe diarrhoea, <sup>2</sup> 133 000 deaths and 8.2M DALYs annually in LMICs <sup>7</sup>	Primary, secondary and tertiary health facilities in LMICs	Diagnosis-based treatment	Not approved in children under 12 months, only ~30% efficacy in malnourished <sup>9</sup>
			Empiric treatment in high-risk populations where diagnostic tools are not available	Insufficient evidence and guidelines
		Community based treatment	Mass drug administration in seasons with high prevalence	Insufficient evidence and guidelines
Malnourished children	Estimated 50 million wasted children globally. <sup>45</sup> Recent studies indicate 10%–20% prevalence of cryptosporidiosis in children with acute malnourishment. <sup>9 46–48</sup>	Primary, secondary and tertiary health facilities in LMICs. Malnutrition care centres in clinics and hospitals	Diagnosis-based treatment	Poorly effective (~30% efficacious) <sup>9</sup>
			Empiric treatment in high-risk populations where diagnostic tools are not available	Insufficient evidence and guidelines. Nitazoxanide poorly effective <sup>9</sup>
Immunocompromised patients	Estimates range from 5% to 50% of PLWHA and up to 30% of solid organ transplant recipients. <sup>49–53</sup>	Primary, secondary and tertiary health facilities in LMICs. HIV/AIDS treatment programmes. Transplant centres in any global setting	Diagnosis-based treatment	Poorly or non-effective for PLWHA <sup>9 43 54</sup>
			Empiric treatment in high-risk populations where diagnostic tools are not available	Insufficient evidence and guidelines Poorly or non-effective for PLWHA <sup>9 43 54</sup>

Adapted from Ashigbie *et al.*<sup>42</sup>  
DALYs, disability-adjusted life years lost; LMICs, low-income and middle-income countries; PLWHA, people living with HIV/AIDS.

seen. In the event that a compound or combination with appropriate safety profile can be developed, mass drug administration could be used, particularly given the high infectivity of the parasite and the fact that many infants are likely to be chronically infected.

Beyond this, the authors believe that *Cryptosporidium* should be formally recognised as a NTD by the WHO, for its major impact is in LMICs and predominantly affects infants and young children. As noted above, *Cryptosporidium* has a very significant impact compared with many other NTDs currently listed by the WHO (figure 2). This status will bring the critical medical need of *Cryptosporidium* treatment to the attention of funding bodies, foundations, international health organisations and pharmaceutical companies. *Cryptosporidium* should also be on the list of tropical infections eligible for a priority review voucher (PRV) by US FDA.<sup>44</sup> The PRV programme has proven to be an important financial incentive to pharmaceutical companies wishing to develop drugs for NTDs.

There are some exciting compounds at a later preclinical or early clinical stage. This calls for more funding to move these leads into clinical trials, to properly evaluate the effect that they will have on millions of people (primarily infants and young children). Going into the clinic will enable us to determine the profile of a drug

that can have clinical impact and to establish a way for its use.

Thus, in summary, using either deaths or DALYs as parameters, the unmet medical need for *Cryptosporidium* infection exceeds that of most NTDs and causes a huge impact on Africa and Asia. The current therapeutic available is inadequate for the vast majority of this unmet medical need. Tenable use case scenarios exist for how more effective therapeutics for *Cryptosporidium* infection could be deployed to reduce deaths and DALYs. *Cryptosporidium* should be recognised as a major unmet medical need and designated a NTD by the WHO and as a tropical disease with PRV status by the US FDA. The fastest way to address the unmet need is to close funding gaps in preclinical candidates and clinical trials, and this should lead to an effective *Cryptosporidium* therapeutic in a few years.

**Collaborators** Cryptosporidiosis Therapeutics Advocacy Group: Samuel L M Arnold, PhD, University of Washington School of Pharmacy; Beatriz Baragana, PhD, University of Dundee; Lynn Barrett, University of Washington; Frederick S Buckner, MD, University of Washington; Jeremy D Burrows, Phil, Medicines for Malaria Venture; Maria A Caravedo, MD, University of Texas Medical Branch; Ryan Choi University of Washington; Robert K M Choy, PhD, PATH; Eugenio de Hostos, PhD, Calibr at Scripps Research; Thierry Diagana, PhD, Global Health, Novartis Institutes for BioMedical Research, Inc.; Suzanne Duce, PhD, University of Dundee; Rashidul Haque, MB, PhD, ICDDR, B; Matthew A Hulverson, University

of Washington; Christopher D Huston, MD, University of Vermont; Pui-Ying D Iroh Tam, DMed, Malawi-Liverpool Wellcome Programme; Paul Kelly, MD, TROPAN, University of Zambin; Tom Kennedy, PhD, Eleven Bravo LLC; Ibrahim A Khalil, MPH, University of Washington; Minju Kim, University of Washington Hans Rosling Center Global Health; Poonum Korpe, MD, Johns Hopkins Bloomberg School of Public Health; Benoît Laleu, PhD, Medicines for Malaria Venture; Diana Lalika, University of Washington; Fabrice Laurent, PhD, INRAE, Univ. of Tours; Case W McNamara, PhD, Calibr at Scripps Research; Marvin J Meyers, PhD, St. Louis University; Roberta M O'Connor, PhD, University of Minnesota; Kayode K Ojo, PhD, University of Washington; Phillip Olias, PhD, Justus-Liebig-University Giessen; Richard Omore, PhD, Kenya Research Institute, Center for Global Health Research; Nede Ovbiebo, University of Washington; James Platts-Mills, MD, University of Virginia; Mattie C Pawlowic, PhD, University of Dundee; William A Petri, Jr MD, PhD, University of Virginia; Gladys Queen, MS, University of Washington; Divya Rao, University of Washington; Kevin Reed, PhD, University of Dundee; Michael W Riggs, DVM, University of Arizona; Jennifer L Roxas, PhD, University of Arizona; Adam Sateriale, PhD, The Francis Crick Institute; Deborah A Schaefer, MS University of Arizona; L David Sibley, PhD, Washington University in St. Louis; Jonathan M Spector, MPH, Global Health, Novartis Institutes for BioMedical Research, Inc.; Chris Tonkin, PhD, The Walter and Eliza Hall Institute of Medical Research; Timilehin E Toye, BPHARM, University of Washington; Saul Tzipori, DVM, PhD, Tufts University; Timothy Wells, PhD, Medicines for Malaria Venture; A Clinton White, MD University of Texas, Medical Branch; Grace S Yang, University of Washington.

**Contributors** WCV made the first draft, modified each draft. IG revised the first draft and led the writing group of the other authors. All the other authors revised the manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Map disclaimer** The inclusion of any map (including the depiction of any boundaries therein), or of any geographic or locational reference, does not imply the expression of any opinion whatsoever on the part of BMJ concerning the legal status of any country, territory, jurisdiction or area or of its authorities. Any such expression remains solely that of the relevant source and is not endorsed by BMJ. Maps are provided without any warranty of any kind, either express or implied.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** No data are available.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Boris Striepen <http://orcid.org/0000-0002-7426-432X>

Wesley C Van Voorhis <http://orcid.org/0000-0001-6141-2015>

## REFERENCES

- Kotloff KL, Nataro JP, Blackwelder WC, *et al*. Burden and Aetiology of Diarrhoeal disease in infants and young children in developing countries (the global Enteric multicenter study, GEMS): a prospective, case-control study. *Lancet* 2013;382:209–22.
- Samba O S, Khitam M, Dilruba N, *et al*. The burden of Cryptosporidium Diarrhoeal disease among children < 24 months of age in moderate/high mortality regions of sub-Saharan Africa and South Asia, utilizing data from the global Enteric multicenter study (GEMS). *PLoS Negl Trop Dis* 2016.
- Khalil IA, Troeger C, Rao PC, *et al*. Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study. *Lancet Glob Health* 2018;6:e758–68.
- Checkley W, Epstein LD, Gilman RH, *et al*. Effects of Cryptosporidium Parvum infection in Peruvian children: growth faltering and subsequent catch-up growth. *Am J Epidemiol* 1998;148:497–506.
- Checkley W, White AC, Jaganath D, *et al*. A review of the global burden, novel diagnostics, Therapeutics, and vaccine targets for Cryptosporidium. *Lancet Infect Dis* 2015;15:85–94.
- Korpe PS, Valencia C, Haque R, *et al*. Epidemiology and risk factors for Cryptosporidiosis in children from 8 low-income sites: results from the MAL-ED study. *Clin Infect Dis* 2018;67:1660–9.
- IHME. Global burden of disease study. 2019. Available: <https://vizhub.healthdata.org/gbd-results/>
- De Rycker M, Baragaña B, Duce SL, *et al*. Challenges and recent progress in drug discovery for tropical diseases. *Nature* 2018;559:498–506.
- Amadi B, Mwiya M, Musuku J, *et al*. Effect of Nitazoxanide on morbidity and mortality in Zambian children with Cryptosporidiosis: a randomised controlled trial. *Lancet* 2002;360:1375–80.
- Schneider A, Wendt S, Lübbert C, *et al*. Current Pharmacotherapy of Cryptosporidiosis: an update of the state-of-the-art. *Expert Opin Pharmacother* 2021;22:2337–42.
- Sparks H, Nair G, Castellanos-Gonzalez A, *et al*. Treatment of Cryptosporidium: what we know, gaps, and the way forward. *Curr Trop Med Rep* 2015;2:181–7.
- Vinayak S, Pawlowic MC, Sateriale A, *et al*. Genetic modification of the Diarrhoeal pathogen Cryptosporidium Parvum. *Nature* 2015;523:477–80.
- Baragaña B, Forte B, Choi R, *et al*. Lysyl-tRNA synthetase as a drug target in malaria and Cryptosporidiosis. *Proc Natl Acad Sci U S A* 2019;116:7015–20.
- Hulverson MA, Vinayak S, Choi R, *et al*. Bumped-kinase inhibitors for Cryptosporidiosis therapy. *J Infect Dis* 2017;215:1275–84.
- Manjunatha UH, Vinayak S, Zambirski JA, *et al*. A Cryptosporidium PI(4)K inhibitor is a drug candidate for Cryptosporidiosis. *Nature* 2017;546:376–80.
- Vinayak S, Jumani RS, Miller P, *et al*. Bicyclic Azetidines kill the Diarrheal pathogen *Cryptosporidium* in mice by inhibiting parasite Phenylalanyl-tRNA synthetase. *Sci Transl Med* 2020;12:eaba8412.
- Wilke G, Funkhouser-Jones LJ, Wang Y, *et al*. A stem-cell-derived platform enables complete *Cryptosporidium* development in vitro and genetic Tractability. *Cell Host Microbe* 2019;26:123–34.
- Bellini V, Swale C, Brenier-Pinchart M-P, *et al*. Target identification of an Antimalarial Oxaborole identifies An13762 as an alternative Chemotype for targeting Cpsf3 in Apicomplexan parasites. *iScience* 2020;23:101871.
- Swale C, Bougdour A, Gnahoui-David A, *et al*. Metal-captured inhibition of pre-mRNA processing activity by Cpsf3 controls *Cryptosporidium* infection. *Sci Transl Med* 2019;11:eaaax7161.
- Arnold SLM, Choi R, Hulverson MA, *et al*. Necessity of bumped kinase inhibitor gastrointestinal exposure in treating *Cryptosporidium* infection. *J Infect Dis* 2017;216:55–63.
- Jumani RS, Hasan MM, Stebbins EE, *et al*. A suite of Phenotypic assays to ensure pipeline diversity when Prioritizing drug-like *Cryptosporidium* growth inhibitors. *Nat Commun* 2019;10:1862.
- Funkhouser-Jones LJ, Ravindran S, Sibley LD. Defining stage-specific activity of potent new inhibitors of *Cryptosporidium Parvum* growth in vitro. *mBio* 2020;11:e00052–20.
- Choudhary HH, Nava MG, Gartlan BE, *et al*. A conditional protein degradation system to study essential gene function in *Cryptosporidium Parvum*. *mBio* 2020;11:e01231–20.
- Love MS, Choy RKM. Emerging treatment options for Cryptosporidiosis. *Curr Opin Infect Dis* 2021;34:455–62.
- Wang B, Castellanos-Gonzalez A, White AC. Novel drug targets for treatment of Cryptosporidiosis. *Expert Opin Ther Targets* 2020;24:915–22.
- Hulverson MA, Choi R, Arnold SLM, *et al*. Advances in bumped kinase inhibitors for human and animal therapy for Cryptosporidiosis. *Int J Parasitol* 2017;47:753–63.
- Hulverson MA, Choi R, McCloskey MC, *et al*. Repurposing infectious disease hits as anti-Cryptosporidium leads. *ACS Infect Dis* 2021;7:1275–82.
- Buckner FS, Ranade RM, Gillespie JR, *et al*. Optimization of methionyl tRNA-synthetase inhibitors for treatment of Cryptosporidium infection. *Antimicrob Agents Chemother* 2019;63:e02061–18.
- Lunde CS, Stebbins EE, Jumani RS, *et al*. Identification of a potent Benzoxaborole drug candidate for treating Cryptosporidiosis. *Nat Commun* 2019;10:2816.
- Guo F, Zhang H, McNair NN, *et al*. The existing drug Vorinostat as a new lead against Cryptosporidiosis by targeting the parasite Histone Deacetylases. *J Infect Dis* 2018;217:1110–7.
- Obloh E, Schubert TJ, Teixeira JE, *et al*. Optimization of the urea Linker of Triazolopyridazine Mmv665917 results in a new Anticryptosporidial lead with improved potency and predicted hERG safety margin. *J Med Chem* 2021;64:11729–45.

- 32 Roestenberg M, Hoogerwerf M-A, Ferreira DM, *et al.* Experimental infection of human volunteers. *Lancet Infect Dis* 2018;18:e312–22.
- 33 McCarthy JS, Rückle T, Djeriou E, *et al.* A phase II pilot trial to evaluate safety and efficacy of Ferroquine against early *Plasmodium falciparum* in an induced blood-stage malaria infection study. *Malar J* 2016;15:469.
- 34 DuPont HL, Chappell CL, Sterling CR, *et al.* The infectivity of *Cryptosporidium Parvum* in healthy volunteers. *N Engl J Med* 1995;332:855–9.
- 35 Chappell CL, Okhuysen PC, Sterling CR, *et al.* Infectivity of *Cryptosporidium Parvum* in healthy adults with pre-existing anti-C. *Parvum* serum immunoglobulin G. *Am J Trop Med Hyg* 1999;60:157–64.
- 36 Chappell CL, Okhuysen PC, Langer-Curry R, *et al.* *Cryptosporidium Hominis*: experimental challenge of healthy adults. *Am J Trop Med Hyg* 2006;75:851–7.
- 37 Jumani RS, Blais J, Tillmann H-C, *et al.* Opportunities and challenges in developing a *Cryptosporidium* controlled human infection model for testing Antiparasitic agents. *ACS Infect Dis* 2021;7:959–68.
- 38 Hasan MM, Stebbins EE, Choy RKM, *et al.* Spontaneous selection of *Cryptosporidium* drug resistance in a calf model of infection. *Antimicrob Agents Chemother* 2021;65:e00023–21.
- 39 Shaw H, ed. A reduction in weight gain in beef calves with clinical *Cryptosporidiosis*. In: *Apicowplexa*. La Escorial, Spain, 2017.
- 40 Shaw HJ, Innes EA, Morrison LJ, *et al.* Long-term production effects of clinical *Cryptosporidiosis* in neonatal calves. *Int J Parasitol* 2020;50:371–6.
- 41 Santin M. *Cryptosporidium* and *Giardia* in ruminants. *Vet Clin North Am Food Anim Pract* 2020;36:223–38.
- 42 Ashigbie PG, Shepherd S, Steiner KL, *et al.* Use-case scenarios for an anti-*Cryptosporidium* therapeutic. *PLoS Negl Trop Dis* 2021;15:e0009057.
- 43 Amadi B, Mwiya M, Sianongo S, *et al.* High dose prolonged treatment with Nitazoxanide is not effective for *Cryptosporidiosis* in HIV positive Zambian children: a randomised controlled trial. *BMC Infect Dis* 2009;9:195.
- 44 Choy RKM, Huston CD. *Cryptosporidiosis* should be designated as a tropical disease by the US food and Drug Administration. *PLoS Negl Trop Dis* 2020;14:e0008252.
- 45 Webb P, Stordalen GA, Singh S, *et al.* Hunger and malnutrition in the 21st century. *BMJ* 2018;361:k2238.
- 46 Bitilinyu-Bangoh J, Voskuil W, Thitiri J, *et al.* Performance of three rapid diagnostic tests for the detection of *Cryptosporidium* Spp. and *Giardia Duodenalis* in children with severe acute malnutrition and diarrhoea. *Infect Dis Poverty* 2019;8:96.
- 47 Jain A, Shah D, Das S, *et al.* Aetiology and outcome of acute diarrhoea in children with severe acute malnutrition: a comparative study. *Public Health Nutr* 2020;23:1563–8.
- 48 Opintan JA, Newman MJ, Ayeh-Kumi PF, *et al.* Pediatric diarrhea in Southern Ghana: etiology and association with intestinal inflammation and malnutrition. *Am J Trop Med Hyg* 2010;83:936–43.
- 49 Amoo JK, Akindele AA, Amoo AOJ, *et al.* Prevalence of Enteric parasitic infections among people living with HIV in Abeokuta, Nigeria. *Pan Afr Med J* 2018;30:66.
- 50 Costa D, Razakandrainibe R, Sautour M, *et al.* Human *Cryptosporidiosis* in immunodeficient patients in France (2015–2017). *Exp Parasitol* 2018;192:108–12.
- 51 Sepahvand F, Mamaghani AJ, Ezatpour B, *et al.* Gastrointestinal parasites in immunocompromised patients; A comparative cross-sectional study. *Acta Trop* 2022;231:106464.
- 52 Wanyiri JW, Kanyi H, Maina S, *et al.* *Cryptosporidiosis* in HIV/AIDS patients in Kenya: clinical features, epidemiology, molecular characterization and antibody responses. *Am J Trop Med Hyg* 2014;91:319–28.
- 53 Wang Z-D, Liu Q, Liu H-H, *et al.* Prevalence of *Cryptosporidium*, *Microsporidia* and *Isospora* infection in HIV-infected people: a global systematic review and meta-analysis. *Parasit Vectors* 2018;11:28.
- 54 Abubakar I, Aliyu SH, Arumugam C, *et al.* Treatment of *Cryptosporidiosis* in immunocompromised individuals: systematic review and meta-analysis. *Br J Clin Pharmacol* 2007;63:387–93.